A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS resultsDavid Cunningham, Eric Van Cutsem, G D’Haens et al.|Journal of Clinical Oncology|2008Cited by 29